STOCK TITAN
  1. Home
  2. Sec-filings
  3. AIM
  4. [EFFECT] AIM ImmunoTech Inc. SEC Filing

[EFFECT] AIM ImmunoTech Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: February 10, 2026 5:00 P.M.
Form: S-1
CIK: 0000946644
Company Name: AIM ImmunoTech Inc.
File Number: 333-292085

Source: View Original Filing on SEC EDGAR

Stock AIM logo
Aim Immunotech

NYSE:AIM

AIM Rankings

#6727 Ranked by Market Cap
N/A Ranked by Dividends
#57 Top Loser

AIM Latest News

Feb 12, 2026
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
Feb 12, 2026
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
Feb 11, 2026
AIM ImmunoTech Announces Commencement of Rights Offering
Feb 6, 2026
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Feb 5, 2026
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM Latest SEC Filings

Feb 10, 2026
[S-1/A] AIM ImmunoTech Inc. Amends IPO Registration Statement
Feb 6, 2026
[Form 4] AIM ImmunoTech Inc. Insider Trading Activity
Feb 5, 2026
[8-K] AIM ImmunoTech Inc. Reports Material Event
Jan 29, 2026
[S-1/A] AIM ImmunoTech Inc. Amends IPO Registration Statement
Jan 23, 2026
[S-1/A] AIM ImmunoTech Inc. Amends IPO Registration Statement

AIM Stock Data

4.25M
3.17M
3.42%
1.68%
1.38%
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
OCALA